
Broncus Holding Corporation
2216.HKHKSEHealthcareMedical - Devices
最新資料
HK$0.645
+HK$0.01 · +1.57%
2216.HK公司概覽
盤中時間採用HKT。市場資料可能有所延遲。
公司概況
公司網站Broncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other international territories. The company's innovative product lineup includes advanced navigation systems such as LungPoint Virtual Bronchoscopic Navigation, a sophisticated computer-assisted image-based software solution. It also offers LungPoint Plus, a system providing real-time airway guidance crucial for lung biopsies and other medical interventions, and LungPro, a virtual bronchoscopic navigation product that enables three-dimensional real-time guided transbronchial needle aspiration alongside proprietary parenchymal navigation. Beyond navigation, Broncus provides a suite of therapeutic products. These feature InterVapor, a targeted bronchoscopic thermal vapor ablation system designed to treat diseased, hyper-inflated lung segments. Additionally, it offers an RF Generator paired with an RF Ablation Catheter, forming a radiofrequency ablation system specifically developed to target lung cancer. The H-Marker, a pulmonary surgical marker, is another key offering. The company further supplies a range of specialized procedural devices, including the BioStarNeedle, a single-use ultrasound-guided aspiration needle for retrieving tissue samples, and the FleXNeedle, a versatile multipurpose biopsy needle. Complementing these are various bronchoscopic accessories like the Archimedes Sheath, a sterile, single-use flexible tube that serves as a working channel during bronchoscopic procedures. The Archimedes Dilation Balloon, another sterile, single-use flexible tube with a distal balloon, is used to dilate target lung tissue within the bronchial tree after insertion through a bronchoscope or sheath. Finally, the Steerable Sheath provides a steerable adjustment handle and an additional working channel. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.
- 產業
- Medical - Devices
- 部門
- Healthcare
- 總部
- CN
- 執行長
- Hong Xu
- 上市以來
- 2021年9月24日
- 僱員
- 191
市場位置
52週區間
目前HK$0.645,
- 開盤價
- HK$0.645
- 前收盤價
- HK$0.635
- 成交量
- 20.25萬
- 0.41× 平均值
- 平均成交量
- 49.85萬
- 日均成交量
- 市值
- 3.4億 HKD
- 貝塔
- 1.19
- 市場參考 1
- 50天平均值
- HK$0.6678
- 低於平均水平-3.41%
- 200天平均值
- HK$1.462
- 低於平均水平-55.88%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 1.16億 USD
- 本益比(TTM)
- -2.22×
- 股價淨值比(TTM)
- 0.27×
- 股價營收比(TTM)
- 248.67×
- EV/EBITDA
- -5.11×
- 盈餘收益率
- -12.09%
- 自由現金流收益率
- -6.79%
- 股息率
- 0.00%
獲利能力和效率
- 毛利率
- -1585.06%
- 營業利益率
- -14017.85%
- 淨利潤率
- -10273.01%
- 股東權益報酬率
- -11.92%
- 資產報酬率
- -11.45%
- 投入資本報酬率
- -16.24%
財務健康
- 負債權益比
- 0×
- 流動比率
- 22.7×
- 奧特曼 Z 分數
- -0.24
- 皮奧特羅斯基 F 分數
- 4 共 9 個
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 17.4萬 USD | 813.1萬 USD | 1025.5萬 USD | 941.3萬 USD | 1089.1萬 USD |
| 銷貨成本 | 109.1萬 USD | 199.2萬 USD | 302.8萬 USD | 209.8萬 USD | 214.9萬 USD |
| 毛利 | −91.7萬 USD | 613.9萬 USD | 722.7萬 USD | 731.5萬 USD | 874.2萬 USD |
| 研究與開發 | 777.2萬 USD | 1147.1萬 USD | 2015.4萬 USD | 1916.7萬 USD | 1675.9萬 USD |
| 銷售、一般及管理費用 | 1570.2萬 USD | 1575.5萬 USD | 2041.5萬 USD | 2041.8萬 USD | 3125.2萬 USD |
| 營業費用 | 2347.4萬 USD | 2862.7萬 USD | 4044.8萬 USD | 4002.3萬 USD | 4617.1萬 USD |
| 利息收入 | 549.01萬 USD | 653.4萬 USD | 604.1萬 USD | 262.8萬 USD | 16.1萬 USD |
| 利息支出 | 4005.9 USD | 8.4萬 USD | 16.3萬 USD | 9.8萬 USD | 17萬 USD |
| 折舊和攤銷 | 170.6萬 USD | 212.2萬 USD | 286.6萬 USD | 213.1萬 USD | 269.1萬 USD |
| 營業利益 | −2439.1萬 USD | −2248.8萬 USD | −3322.1萬 USD | −3270.8萬 USD | −3985.3萬 USD |
| 淨利 | −1787.5萬 USD | −1530.3萬 USD | −2809.1萬 USD | −2803.6萬 USD | −2.36億 USD |
公司資料更新於 2026年8月24日。
2216.HK同業公司
持有2216.HK的ETF
報告持有此股票曝險的交易所交易基金。
繼續GoAI的研究
在 GoAI 中研究2216.HKresearch.disclaimer







